Laida Cuevas Palomares
Quick facts
Marketed products
- RiTUXimab Injection [Truxima] · Oncology, Immunology
Rituximab is a chimeric monoclonal antibody that binds to CD20 on B cells, leading to their depletion through antibody-dependent cellular cytotoxicity and direct apoptosis.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: